Evidence map›Paper›PMID 36266386›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.

Cheng-Bang Wang, Shao-Hua Chen, Lin Zhao, Xin Jin, Xi Chen, Jin Ji, Zeng-Nan Mo, Fu-Bo Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Cheng-Bang Wang *Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shao-Hua Chen *Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lin Zhao *Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.
Xin JinDepartment of Urology, Zhongda Hospital, Southeast University, Nanjing, 210009, China.
Xi ChenDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.
Jin JiDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.
Zeng-Nan MoDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. mozengnan@gxmu.edu.com.
Fu-Bo WangDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. wangfubo@gxmu.edu.cn.ORCID http://orcid.org/0000-0002-2209-9932
Guangxi Medical University · CNSecond Military Medical University · CNNantong University · CN

Funding

National Natural Science Foundation of China 81902616Science and Technology Major Project of Guangxi AA22096032Science and Technology Major Project of Guangxi AA22398
6 · The paper itself

Abstract

purposeIt is well-established that the lack of accurate diagnostic modalities for prostate cancer (PCa) leads to overdiagnosis and overtreatments. Accordingly, this study aimed to assess the value of urine-derived exosomal prostate-specific membrane antigen (PSMA) as a biomarker for the diagnosis of PCa and clinically significant prostate cancer (csPCa).

methodsA total of 284 urine samples were collected from patients after the digital rectal examination (DRE). Urinary exosomes were extracted using commercial kits, and urine-derived exosomal PSMA was determined via enzyme-linked immunosorbent assay (ELISA). Evaluation of diagnostic accuracy of PSMA was performed via receiver operating characteristic (ROC) analysis, decision curve analysis (DCA), and waterfall plots.

resultsWe found that urine-derived exosomal PSMA was significantly higher in PCa and csPCa than in benign prostatic hyperplasia (BPH) and BPH + non-aggressive prostate cancer (naPCa) groups (P < 0.001). Furthermore, the urine-derived exosome PSMA yielded area under the ROC curve (AUC) values of 0.876 and 0.826 for detecting PCa and csPCa, respectively, suggesting better performance than traditional clinical biomarkers. Besides, when the cutoff value used corresponded to a sensitivity of 95%, urine-derived exosomal PSMA could avoid unnecessary biopsies in 41.2% of cases and missed only 0.7% of csPCa cases.

conclusionsUrine-derived exosomal PSMA exhibits a good diagnostic yield for detecting PCa and csPCa. Findings of the present study provide the foothold for future studies on cancer management and research in this patient population.

Indexed as

ExosomesProstatic HyperplasiaProstatic NeoplasmsBiomarkersBiopsyHumansMaleProstate-Specific AntigenBiomarkersProstate-Specific AntigenClinically significant prostate cancerDiagnostic biomarkerLiquid biopsyProstate-specific membrane antigenUrine-derived exosomes

Identifiers

PMID36266386
OpenAlexW4306896913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.